Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment
Mirella Alpa, Dario Roccatello Centro di Ricerche di Immunopatologia e Documentazione su Malattie Rare (CMID), Struttura Complessa Direzione Universitaria di Immunologia Clinica, Università di Torino e Ospedale G Bosco, Torino, ItalyAbstract: Familial Mediterranean fever is an autosomal r...
Saved in:
Main Authors: | Alpa M (Author), Roccatello D (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2015-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases
by: Burcu Bozkaya Yücel, et al.
Published: (2021) -
Two Sisters with Colchicine-Resistant form of Familial Mediterranean Fever on the Canakinumab Therapy: Clinical Case
by: Elena A. Ligostaeva, et al.
Published: (2020) -
The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
by: Kacar M, et al.
Published: (2020) -
Treatment of refractory Yao syndrome with canakinumab
by: Caroline J. Brailsford, MS, et al.
Published: (2022) -
Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience
by: Gülşah Kavrul Kayaalp, et al.
Published: (2023)